A recent study demonstrated that the deletion of hepatic Pparα in mice results in enhanced liver steatosis because of the impaired oxidation of FFA [30], underscoring the relevance and potential of hepatocyte PPARα as a drug target for NAFLD. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.